Cadrenal Therapeutics Q2 net loss narrows 9.39% to $3.3 million
CVKD•Cash position and runway
Cash and cash equivalents were about $4.2 million in early August, and the company said its runway is expected to extend through Q1 2027 under the current plan.
Q2 loss narrows as expenses decline
Cadrenal Therapeutics posted a second-quarter net loss of $3.32 million, narrowing from $3.67 million a year earlier.
Operating loss narrowed to $3.34 million as total operating expenses fell to $3.34 million from $3.73 million.
Research and development spending dropped to $705,151 from $1.08 million, while general and administrative expense edged down to $2.63 million from $2.66 million.
Partnering process launched for pipeline assets
Cadrenal launched a structured partnering process for CAD-1005, frunexian and tecarfarin following Phase 2 CAD-1005 data showing more than a 25% thrombotic-event reduction.
Related News
Bird remains found aboard 737 engine from Ryanair Greek incident
BA•
U.S. FDA Grants Accelerated Approval To Bristol Myers Squibb's First Celmod Therapy Zenbexus™, In Combination With Daratumumab And Hyaluronidase-Fihj And Dexamethasone (Zdd) For Patients With Multiple Myeloma, As Early As First Relapse
BMY•
